CO4700289A1 - TACHYCININ AMIDA ANTAGONISTS WHO HAVE TACHYCININ ANTAGONIST ACTIVITY - Google Patents
TACHYCININ AMIDA ANTAGONISTS WHO HAVE TACHYCININ ANTAGONIST ACTIVITYInfo
- Publication number
- CO4700289A1 CO4700289A1 CO95058767A CO95058767A CO4700289A1 CO 4700289 A1 CO4700289 A1 CO 4700289A1 CO 95058767 A CO95058767 A CO 95058767A CO 95058767 A CO95058767 A CO 95058767A CO 4700289 A1 CO4700289 A1 CO 4700289A1
- Authority
- CO
- Colombia
- Prior art keywords
- tachycinin
- amida
- antagonists
- sulfur
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Abstract
1. UN COMPUESTO DE LA FORMULA I FIGURA 1 EN LA QUE R1 ES FENILO MONO O DISUSTITUIDO POR UNO O DOS MIEMBROS SELECCIONADOS DEL GRUPO QUE CONSISTE DE HALOGENO, NITRO, CIANO, TRIFLUOROMETILO, HIDROZI, METOXI, HIDROXIMETILO, METOXIMETILO, METOXICARBO- LO, CARBAMOILO Y N-METILCARBAMOILO, n ES CERO o 1 X1 ES OXIGENO, AZUFRE O =NCN, X2 Y X3 SON CADA UNO INDEPENDIENTEMENTE OXIGENO O AZUFRE, R2 ES HIDROGENO O METILO, R3 ES FENILO, FENILO SUSTITUIDO CON HALO, 2-NAFTI- LO, 1H-INDOL-3-ILO O 1-METIL-INDOL-3-ILO, Z ES -N(CH3)o -CH2-, R4 ES FENILO, 3,5-BIS(TRIFLUOROMETIL)FENILO O PI- RIDILO, Y R5 ES HIDROGENO, FENILO 3,5-BIS(TRIFLUOROMETIL) FENILO O PIRIDILO, POR LO QUE, CUANDO X3 ES AZUFRE, Z ES -N(CH3)-, O UNA SAL DE ADICION DE ACIDO DEL MISMO.1. A COMPOUND OF FORMULA I FIGURE 1 IN WHICH R1 IS MONO PHENYLUS OR DISSTITUTED BY ONE OR TWO SELECTED MEMBERS OF THE GROUP THAT CONSISTS OF HALOGEN, NITRO, CIANO, TRIFLUOROMETILO, HIDROZIME, METHYLOX, CARBAMOIL AND N-METHYL CARBAMOYL, n IS ZERO or 1 X1 IS OXYGEN, SULFUR O = NCN, X2 AND X3 ARE EACH INDEPENDENTLY OXYGEN OR SULFUR, R2 IS HYDROGEN OR METHYL, R3 IS FENYL-FUTHYL-SUBSTITUTE LO, 1H-INDOL-3-ILO OR 1-METHYL-INDOL-3-ILO, Z ES -N (CH3) or -CH2-, R4 ES FENILO, 3,5-BIS (TRIFLUOROMETIL) FENILO OR PI- RIDILO, AND R5 IS HYDROGEN, PHENYL 3,5-BIS (TRIFLUOROMETIL) PHENYL OR PYRIDILE, SO, WHEN X3 IS SULFUR, Z IS -N (CH3) -, OR AN ADDITION SALT OF THE SAME ACID.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9425085.9A GB9425085D0 (en) | 1994-12-13 | 1994-12-13 | Organic compounds |
GBGB9426016.3A GB9426016D0 (en) | 1994-12-22 | 1994-12-22 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CO4700289A1 true CO4700289A1 (en) | 1998-12-29 |
Family
ID=26306161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO95058767A CO4700289A1 (en) | 1994-12-13 | 1995-12-12 | TACHYCININ AMIDA ANTAGONISTS WHO HAVE TACHYCININ ANTAGONIST ACTIVITY |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0797583A1 (en) |
JP (1) | JPH10511935A (en) |
AR (1) | AR001332A1 (en) |
AU (1) | AU4343796A (en) |
BR (1) | BR9509997A (en) |
CA (1) | CA2204130A1 (en) |
CO (1) | CO4700289A1 (en) |
CZ (1) | CZ179097A3 (en) |
FI (1) | FI971685A (en) |
HU (1) | HUT77002A (en) |
IL (1) | IL116323A0 (en) |
NO (1) | NO972526L (en) |
PE (1) | PE38997A1 (en) |
PL (1) | PL320217A1 (en) |
SK (1) | SK74697A3 (en) |
TR (1) | TR199501568A2 (en) |
WO (1) | WO1996018643A1 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
WO1998015277A2 (en) * | 1996-10-07 | 1998-04-16 | Merck Sharp & Dohme Limited | Cns-penetrant nk-1 receptor antagonists as antidepressant and/or an anti-anxiety agents |
WO2000048623A1 (en) | 1999-02-18 | 2000-08-24 | Kaken Pharmaceutical Co., Ltd. | Novel amide derivatives as growth hormone secretagogues |
KR101412339B1 (en) | 2004-07-15 | 2014-06-25 | 알바니 몰레큘라 리써치, 인크. | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
CN101495184A (en) | 2005-07-15 | 2009-07-29 | Amr科技公司 | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
SI2805945T1 (en) | 2007-01-10 | 2019-09-30 | Msd Italia S.R.L. | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
WO2008090117A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
CA2690191C (en) | 2007-06-27 | 2015-07-28 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
CA2717509A1 (en) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
EP2413932A4 (en) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | Inhibitors of akt activity |
US9034899B2 (en) | 2009-05-12 | 2015-05-19 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
US8815894B2 (en) | 2009-05-12 | 2014-08-26 | Bristol-Myers Squibb Company | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
CA2760837C (en) | 2009-05-12 | 2018-04-03 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
CA2777043C (en) | 2009-10-14 | 2015-12-15 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
US8518907B2 (en) | 2010-08-02 | 2013-08-27 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
EP2606134B1 (en) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
WO2012036997A1 (en) | 2010-09-16 | 2012-03-22 | Schering Corporation | Fused pyrazole derivatives as novel erk inhibitors |
EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
WO2012143879A1 (en) | 2011-04-21 | 2012-10-26 | Piramal Healthcare Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
WO2013165816A2 (en) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
AU2013323508B2 (en) | 2012-09-28 | 2017-11-02 | Merck Sharp & Dohme Corp. | Novel compounds that are ERK inhibitors |
ES2651347T3 (en) | 2012-11-28 | 2018-01-25 | Merck Sharp & Dohme Corp. | Compositions and methods for cancer treatment |
CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
EP3525785A4 (en) | 2016-10-12 | 2020-03-25 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5164372A (en) * | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
JPH05186498A (en) * | 1991-12-27 | 1993-07-27 | Japan Tobacco Inc | Proline derivative |
-
1995
- 1995-12-11 IL IL11632395A patent/IL116323A0/en unknown
- 1995-12-11 PE PE1995286859A patent/PE38997A1/en not_active Application Discontinuation
- 1995-12-12 SK SK746-97A patent/SK74697A3/en unknown
- 1995-12-12 AU AU43437/96A patent/AU4343796A/en not_active Abandoned
- 1995-12-12 PL PL95320217A patent/PL320217A1/en unknown
- 1995-12-12 JP JP8518261A patent/JPH10511935A/en active Pending
- 1995-12-12 WO PCT/EP1995/004910 patent/WO1996018643A1/en not_active Application Discontinuation
- 1995-12-12 EP EP95942131A patent/EP0797583A1/en not_active Withdrawn
- 1995-12-12 HU HU9701897A patent/HUT77002A/en unknown
- 1995-12-12 BR BR9509997A patent/BR9509997A/en not_active Application Discontinuation
- 1995-12-12 CZ CZ971790A patent/CZ179097A3/en unknown
- 1995-12-12 CO CO95058767A patent/CO4700289A1/en unknown
- 1995-12-12 CA CA002204130A patent/CA2204130A1/en not_active Abandoned
- 1995-12-13 AR AR33458995A patent/AR001332A1/en unknown
- 1995-12-13 TR TR95/01568A patent/TR199501568A2/en unknown
-
1997
- 1997-04-18 FI FI971685A patent/FI971685A/en not_active Application Discontinuation
- 1997-06-03 NO NO972526A patent/NO972526L/en unknown
Also Published As
Publication number | Publication date |
---|---|
SK74697A3 (en) | 1997-11-05 |
BR9509997A (en) | 1997-12-30 |
CA2204130A1 (en) | 1996-06-20 |
HUT77002A (en) | 1998-03-02 |
AU4343796A (en) | 1996-07-03 |
IL116323A0 (en) | 1996-03-31 |
JPH10511935A (en) | 1998-11-17 |
NO972526D0 (en) | 1997-06-03 |
CZ179097A3 (en) | 1997-10-15 |
NO972526L (en) | 1997-06-03 |
FI971685A0 (en) | 1997-04-18 |
FI971685A (en) | 1997-08-13 |
WO1996018643A1 (en) | 1996-06-20 |
PL320217A1 (en) | 1997-09-15 |
EP0797583A1 (en) | 1997-10-01 |
PE38997A1 (en) | 1997-10-02 |
MX9703957A (en) | 1997-09-30 |
TR199501568A2 (en) | 1996-07-21 |
AR001332A1 (en) | 1997-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO4700289A1 (en) | TACHYCININ AMIDA ANTAGONISTS WHO HAVE TACHYCININ ANTAGONIST ACTIVITY | |
IL135333A0 (en) | Acylsulfamoyl benzoic acid amides, plant protection agents containing said acylsulfamoyl benzoic acid amides, and method for producing the same | |
DK0674641T3 (en) | Pyrrolopyrimidines as CRF antagonists | |
PT750618E (en) | OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM | |
DE3868076D1 (en) | HETEROCYCLIC DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND FUNGICIDES CONTAINING THEM AS ACTIVE INGREDIENTS. | |
DK0641328T3 (en) | Bridged, azabicyclic derivatives as substance P antagonists | |
NO307884B1 (en) | Substituted pyrazoles as CRF antagonists | |
ATE180773T1 (en) | N-SULFONYL-2-OXOINDOLE DERIVATIVES WITH AN AFFINITY FOR THE VASOPRESSIN AND/OR OCYTOCIN RECEPTORS | |
DE69203104D1 (en) | Manufacture of cellular elastomers and chemical compositions for their manufacture. | |
ES2097174T3 (en) | DERIVATIVES OF 2-CICLOHEXAN-1-IL AMINA. | |
FI974447A (en) | Semicarbazones having central nervous system activity and pharmaceutical preparations containing them | |
ATE156818T1 (en) | POLYFLUORALKYLTHIOPOLY(ETHYLIMIDAZOLIUM) COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS BIOCIDAL AGENTS | |
ES2056783T3 (en) | SUBSTITUTED DERIVATIVES OF BENZOIC ACID WITH CARDIOVASCULAR ACTIVITY. | |
DE69229339D1 (en) | CRYSTALLINE TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PRODUCTION AND USE | |
ATE81344T1 (en) | 2,3-DISUBSTITUTED ISOXAZOLIDINES, PROCESS FOR THEIR MANUFACTURE, AGENTS CONTAINING THESE AND THEIR USE. | |
ES2111930T3 (en) | AMP ACID ANTAGONISTS AND TREATMENT PROCEDURES WITH THE HELP OF THESE. | |
ATE11134T1 (en) | 1-(3-HALOGEN-2-PYRIDINYL)PIPERAZINE, PROCESS FOR THEIR PREPARATION AND MEDICATIONS CONTAINING THEM. | |
ATE37182T1 (en) | IMIDAZOLINONES AND IMIDAZOLIDINTHIONES, PROCESSES FOR THEIR PREPARATION AND USE OF THESE COMPOUNDS AS HERBICIDES. | |
SE8500107D0 (en) | NEW 8ALFA-ACYLAMINOERGOLINE | |
PT861250E (en) | AMIDINE AND ISOTIOUREIA DERIVATIVES AS NITRIC OXIDE INHIBITORS | |
ES8104995A1 (en) | 2-Hydroxy-5-(1-hydroxy-2-piperazinylethyl)-benzoic acid derivatives | |
CO4761039A1 (en) | FUNGICIDE MIXTURES CONTAINING CARBAMATES AND AMIDES OF CARBOXYLIC ACID | |
ES2054186T3 (en) | ANTIHEPATOPATHIC COMPOSITION. | |
ES8305316A1 (en) | Use of guanidines for manufacturing antidiarrhoeal medicaments and antidiarrhoeal compositions containing these guanidines. | |
ATE144510T1 (en) | N-(ISOCHINOLEIN-5-YL)-SULFONYL AZAZYKLOALKANES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |